Review of the limitations and possible toxicities with CAR-T treatment. ICANs and CRS, while treatable, are very important to educate and understand. This is part of the intersection of heme/onc and rheum. https://t.co/itbwLdHuqf

A#2545 IV SEC for SpA #ACR23 @Rheumow Approved by FDA, though diff dose Who: Medicare/cost/QoL benefit for IV or obese (wt based dose) W16: 41% ASAS40 v 23% PBO W16, PBO switched to SEC. Efficacy W52 (SEC 67%, PBO/Sec 75%) SAE 6%, discontinuation 3.5% #ACRBest https://t.co/ruW0ys49gk

Intriguing data on #GCA treated with tocilizumab #aneurysm still occurs #vasculitis https://t.co/6cPlFRReLJ

• https://twitter.com/MdWarrington/status/1724583931604058194/photo/1
• https://twitter.com/MdWarrington/status/1724583931604058194/photo/1
• https://twitter.com/MdWarrington/status/1724583931604058194/photo/1

Nepal et al. No increased risk of GI perforation for tocilizumab in GCA HR 1.05 . Diverticulitis (RR 3.51), IV methylprednisolone (RR 5.41) risk factors. This fits with my priors, steroids are a bigger risk than tocilizumab. Abstr#2560 #ACR23 @RheumNow https://t.co/BAmBQA0kEP https://t.co/zRjmDIkOHp

Is rituximab still a problem with COVID - esp if our patients have been vaccinated pre-ritux? Antibody titres better when not getting regular ritux around boosters Maybe boosters 9mo (or so) gap after ritux helps immunogenicity @TroldborgAnne et al #ACR23 ABST2511 @RheumNow https://t.co/dE0uC6B9hx

What do we know about IL1 drugs in #OA only a small few stidies prior to CANTOS . COLCHCINE didnt seem to work LoDoCO2 post hoc analysis may work? @RheumNow #ACR23 https://t.co/h4oVRppI5S

APTURA 1 study of tocilizumab biosimilar. Not surprisingly no difference. I'm excited about this product. Hopefully be the end to our tocilizumab supply issues and significant societal savings Abstr#0445 #ACR23 @RheumNow https://t.co/qvP7LCeAkm https://t.co/Zb1FUAlXlz

TM84 #ACR23 @RheumNow 49F MS on RTX, severe arthralgias/wt loss, BMI 18. Spontaneous peritonitis, aseptic discitis/osteo, distal radius lucency, hyperammonemia, hypogammaglobulinemia w 1 yr arthritis Dx: Mycoplasma: ureaplasma urealyticam on culture, PCR improved https://t.co/jM0sARLZS7

Retrospective database study from Japan of PsA pts: At 12/24 mos ffg tx initiation, 37.5%/49% of pts discontinued index bDMARD while 22.2%/31.2% switched tx. Dc rates lowest for risankizumab 🤔Reasons for switching/discontinuation not mentioned. #ACR23 ABST2246 @RheumNow https://t.co/6dhKZmp1wE